Insight into the heterogeneity of breast cancer through next-generation sequencing
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Rapid and sophisticated improvements in molecular analysis have allowed us to sequence whole human genomes as well as cancer genomes, and the findings suggest that we may be approaching the ability to individualize the diagnosis and treatment of cancer. This paradigmatic shift in approach will require clinicians and researchers to overcome several challenges including the huge spectrum of tumor types within a given cancer, as well as the cell-to-cell variations observed within tumors. This review discusses how next-generation sequencing of breast cancer genomes already reveals insight into tumor heterogeneity and how it can contribute to future breast cancer classification and management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray
Schena, M., Shalon, D., Davis, R. W., & Brown, P. O. (1995) · Science · doi:10.1126/science.270.5235.467 · Cited by 9,609
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Tumour evolution inferred by single-cell sequencing
Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., Cook, K., Stepansky, A., Levy, D., Esposito, D., et al. (2011) · Nature · doi:10.1038/nature09807 · Cited by 2,598
Self-citationMassive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414
International network of cancer genome projects
The International Cancer Genome Consortium (2010) · Nature · doi:10.1038/nature08987 · Cited by 2,299
kConFab, Lim, E., Vaillant, F., Wu, D., Forrest, N. C., Pal, B., Hart, A. H., Asselin-Labat, M.-L., Gyorki, D. E., Ward, T., et al. (2009) · Nature Medicine · doi:10.1038/nm.2000 · Cited by 1,492
Cited by
Intra-tumour heterogeneity: a looking glass for cancer?
Marusyk, A., Almendro, V., & Polyak, K. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3261 · Cited by 2,000
Heterogeneity in breast cancer
Polyak, K. (2011) · Journal of Clinical Investigation · doi:10.1172/jci60534 · Cited by 1,006
Cancer heterogeneity: implications for targeted therapeutics
Fisher, R., Pusztai, L., & Swanton, C. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.581 · Cited by 978
Clinical management of breast cancer heterogeneity
Zardavas, D., Irrthum, A., Swanton, C., & Piccart, M. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.73 · Cited by 570
[Retracted] Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures
Kashyap, D., Pal, D., Sharma, R., Garg, V. K., Goel, N., Koundal, D., Zaguia, A., Koundal, S., & Belay, A. (2022) · BioMed Research International · doi:10.1155/2022/9605439 · Cited by 529
RetractedCellular Heterogeneity and Molecular Evolution in Cancer
Almendro, V., Marusyk, A., & Polyak, K. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-163923 · Cited by 498
Wang, T., Gilkes, D. M., Takano, N., Xiang, L., Luo, W., Bishop, C. J., Chaturvedi, P., Green, J. J., & Semenza, G. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410041111 · Cited by 493
“, triple negative) and are classified as basallike/claudin-low subtype by gene expression criteria (43, 44).”
BackgroundSamanta, D., Gilkes, D. M., Chaturvedi, P., Xiang, L., & Semenza, G. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421438111 · Cited by 460
“TNBCs are characterized by an increased percentage of BCSCs and, at the molecular level, by a gene expression profile known as the basal molecular subtype (10, 11).”
BackgroundRetractedEccles, S. A., Aboagye, E. O., Ali, S., Anderson, A. S., Armes, J., Berditchevski, F., Blaydes, J. P., Brennan, K., Brown, N. J., Bryant, H. E., et al. (2013) · Breast Cancer Research · doi:10.1186/bcr3493 · Cited by 421
Suda, K., Nakaoka, H., Yoshihara, K., Ishiguro, T., Tamura, R., Mori, Y., Yamawaki, K., Adachi, S., Takahashi, T., Kase, H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.037 · Cited by 414
“Such analyses together with multiregional sampling from the same individuals will be useful to show how the genomes of endometriosis and normal uterine endometrium evolve through space and time (Russnes et al., 2011; Yates and Campbell, 2012).”
Molecular and Cellular Heterogeneity in Breast Cancer
Rivenbark, A. G., O’Connor, S. M., & Coleman, W. B. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.08.002 · Cited by 327
Molecularly targeted cancer therapy: some lessons from the past decade
Huang, M., Shen, A., Ding, J., & Geng, M. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.11.004 · Cited by 291
Bioinformatics and Computational Tools for Next-Generation Sequencing Analysis in Clinical Genetics
Pereira, R., Oliveira, J., & Sousa, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010132 · Cited by 279
Established breast cancer risk factors and risk of intrinsic tumor subtypes
Barnard, M. E., Boeke, C. E., & Tamimi, R. M. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.06.002 · Cited by 278
Mroz, E. A., Tward, A. D., Pickering, C. R., Myers, J. N., Ferris, R. L., & Rocco, J. W. (2013) · Cancer · doi:10.1002/cncr.28150 · Cited by 220
Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments
Testa, U., Castelli, G., & Pelosi, E. (2020) · Medical Sciences · doi:10.3390/medsci8010018 · Cited by 214
“The stratification of these patients according to expression subtypes, showed that TP53 mutation is more frequent in basal-like and HER2-enriched disease, while the PI3KCA mutation is more frequent among luminal A tumors [37].”
BackgroundMolecular characterization and targeted therapeutic approaches in breast cancer
Toss, A., & Cristofanilli, M. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0560-9 · Cited by 170
“Lastly, in the mutator hypothesis, tumor mass develops because of the gradual and random accumulation of genetic mutations, causing a wide range of diversity [40].”
BackgroundBreast cancer stem cells, heterogeneity, targeting therapies and therapeutic implications
Zeng, X., Liu, C., Yao, J., Wan, H., Wan, G., Li, Y., & Chen, N. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2020.105320 · Cited by 164
Omics Technologies Improving Breast Cancer Research and Diagnostics
Orsini, A., Diquigiovanni, C., & Bonora, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612690 · Cited by 52
“sc-seq unmasks the heterogeneity of BC cells, including the identification of rare cell populations, the characterization of cell subtypes and the identification of driver mutations [58,59].”
Hepatic resection for breast cancer liver metastases: Impact of intrinsic subtypes
Chun, Y. S., Mizuno, T., Cloyd, J. M., Ha, M. J., Omichi, K., Tzeng, C.-W. D., Aloia, T. A., Ueno, N. T., Kuerer, H. M., Barcenas, C. H., et al. (2020) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2020.03.214 · Cited by 32
“Due to the higher cost and limited availability of molecular profiling, immunohistochemical classification of intrinsic subtypes by estrogen and progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status is recommended to approximate intrinsic subtypes [12-14].”
BackgroundEvolution of chromosome-arm aberrations in breast cancer through genetic network rewiring
Kuzmin, E., Baker, T. M., Lesluyes, T., Monlong, J., Abe, K. T., Coelho, P. P., Schwartz, M., Del Corpo, J., Zou, D., Morin, G., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113988 · Cited by 20
Metadata
- Authors
- Russnes, H. G., Navin, N., Hicks, J., & Borresen-Dale, A.-L.
- Venue
- Journal of Clinical Investigation
- Published
- 2011-10-03
- Volume
- 121
- Issue
- 10
- Pages
- 3810-3818
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1964302896
- Cited by
- 240
- References
- 7
- FWCI
- 7.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.